Finally, it has been also reported that a proteasome inhibitor, bortezomib showed its anti-tumor efficacy by hyperactivating Hsp60 and HSP90 expression on the surface of cancer cells leading to phagocytosis in murine model of ovarian cancer [227]. Here, HSP90AA1 is linked to cancer.